Hormone Replacement Therapy to Tackle MASLD Progression in Peri‐Menopausal Women: Window of Opportunity or Call for Precision?
Liver International · 2026-04 · 46 (4)
DOI: 10.1111/liv.70616 ↗Kurz gefasst
Editorial in der Zeitschrift Liver International, online erschienen am 26.03.2026. Verfasst von Lanlan Chen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology and Gastroenterology, Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum (CVK) and Campus Charité Mitte (CCM), Be…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Deutsche Forschungsgemeinschaft, China Scholarship Council, First Hospital of Jilin University.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Hepatology and Gastroenterology, Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum (CVK) and Campus Charité Mitte (CCM), Berlin, Germany.
- Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, the First Hospital of Jilin University, Changchun, China.
ORCID-Profile: Frank Tacke
Förderung
- Deutsche Forschungsgemeinschaft
- China Scholarship Council
- First Hospital of Jilin University
Zitieren
APA
Chen, L., & Tacke, F. (2026). Hormone Replacement Therapy to Tackle MASLD Progression in Peri‐Menopausal Women: Window of Opportunity or Call for Precision?. Liver International, 46(4). https://doi.org/10.1111/liv.70616
Vancouver
Chen L, Tacke F. Hormone Replacement Therapy to Tackle MASLD Progression in Peri‐Menopausal Women: Window of Opportunity or Call for Precision?. Liver International. 2026;46(4). doi:10.1111/liv.70616
BibTeX
@article{Chen2026,
author = {Chen, Lanlan and Tacke, Frank},
title = {Hormone Replacement Therapy to Tackle MASLD Progression in Peri‐Menopausal Women: Window of Opportunity or Call for Precision?},
journal = {Liver International},
year = {2026},
volume = {46},
number = {4},
doi = {10.1111/liv.70616}
}
EUVIMED